Stage II differentiated thyroid cancer: A mixed bag

Area of Science:

• Oncology
• Endocrinology
• Cancer Research

Background:

• Well-differentiated thyroid cancer (WDTC) staging by AJCC-TNM system.
• Stage II WDTC definition includes specific criteria for age and metastasis.
• Understanding prognostic differences within WDTC is crucial for patient management.

Purpose of the Study:

• To evaluate the oncological outcomes of stage II WDTC.
• To compare the outcomes of metastatic WDTC in younger (stage II) versus older (stage IVC) patients.
• To identify prognostic factors influencing survival in WDTC.

Main Methods:

• Retrospective analysis of 2,128 WDTC patient cases diagnosed between 1970-2010.
• Inclusion of 215 stage II WDTC and 61 metastatic WDTC cases.
• Application of Cox proportional hazard models and Kaplan-Meier method for survival analysis (DSS and DFS).

Main Results:

• 15-year disease-specific survival (DSS) for metastatic and non-metastatic stage II WDTC was 41.7% and 96.7%, respectively.
• Metastatic stage II WDTC demonstrated a 52-fold increased risk of death compared to non-metastatic cases.
• The DSS for metastatic stage II WDTC was comparable to that of stage IVC WDTC.

Conclusions:

• Metastatic stage II WDTC represents a distinct clinical entity with significantly poorer outcomes.
• Oncological outcomes for metastatic stage II WDTC align closely with those of stage IVC WDTC.
• Distinguishing metastatic from non-metastatic stage II WDTC is critical for accurate prognostication.